Literature DB >> 20880264

Association between comorbidity and clinical characteristics of MS.

R A Marrie1, R I Horwitz, G Cutter, T Tyry, T Vollmer.   

Abstract

BACKGROUND: Comorbidity may be associated with the clinical phenotype of disease and may affect prognostication and treatment decisions. Using the North American Research Committee on Multiple Sclerosis Registry, we described comorbidities present at onset and diagnosis of multiple sclerosis (MS) and examined whether comorbidities present at onset were associated with clinical course or age of MS symptom onset.
METHODS: In 2006, 8983 participants reported their physical and mental comorbidities; smoking status; height; and past and present weight. We compared clinical course at onset and age of symptom onset by comorbidity status.
RESULTS: At MS onset, a substantial proportion of participants had physical (24%) or mental (8.4%) comorbidities. The mean (SD) age of MS onset was 31.2 (9.0) years. Vascular, autoimmune, cancer, visual, and musculoskeletal comorbidities were associated with a later age of symptom onset. Among men and women, the odds of a relapsing course at onset were increased if mental comorbidities (OR 1.48; 1.08-2.01) were present at symptom onset. In women, gastrointestinal comorbidities (OR 1.78; 1.25-2.52) and obesity (OR 2.08 1.53-2.82) at MS onset were also associated with a relapsing course at onset.
CONCLUSIONS: Comorbidity is frequently present at onset of MS and is associated with differences in clinical characteristics.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2010        PMID: 20880264      PMCID: PMC3394540          DOI: 10.1111/j.1600-0404.2010.01436.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  32 in total

1.  The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research.

Authors:  Oliver Sangha; Gerold Stucki; Matthew H Liang; Anne H Fossel; Jeffrey N Katz
Journal:  Arthritis Rheum       Date:  2003-04-15

2.  Patients with Multiple Sclerosis and concomitant uveitis/periphlebitis retinae are not distinct from those without intraocular inflammation.

Authors:  S Schmidt; L Wessels; A Augustin; T Klockgether
Journal:  J Neurol Sci       Date:  2001-06-15       Impact factor: 3.181

3.  Can comorbidity be measured by questionnaire rather than medical record review?

Authors:  J N Katz; L C Chang; O Sangha; A H Fossel; D W Bates
Journal:  Med Care       Date:  1996-01       Impact factor: 2.983

4.  Prevalence of selected chronic conditions: United States, 1986-88.

Authors:  J G Collins
Journal:  Vital Health Stat 10       Date:  1993-02

5.  Validation of a self-report comorbidity questionnaire for multiple sclerosis.

Authors:  Myles Horton; Richard A Rudick; Claire Hara-Cleaver; Ruth Ann Marrie
Journal:  Neuroepidemiology       Date:  2010-06-15       Impact factor: 3.282

Review 6.  Hormonal factors in susceptibility to multiple sclerosis.

Authors:  P Duquette; M Girard
Journal:  Curr Opin Neurol Neurosurg       Date:  1993-04

7.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

8.  The risk of multiple sclerosis in bereaved parents: A nationwide cohort study in Denmark.

Authors:  J Li; C Johansen; H Brønnum-Hansen; E Stenager; N Koch-Henriksen; J Olsen
Journal:  Neurology       Date:  2004-03-09       Impact factor: 9.910

9.  Agreement of self-reported medical history: comparison of an in-person interview with a self-administered questionnaire.

Authors:  Manuela M Bergmann; Eric J Jacobs; Kurt Hoffmann; Heiner Boeing
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

10.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

View more
  24 in total

1.  Change and onset-type differences in the prevalence of comorbidities in people with multiple sclerosis.

Authors:  Lara Marie Pangan Lo; Bruce V Taylor; Tania Winzenberg; Andrew J Palmer; Leigh Blizzard; Ingrid van der Mei
Journal:  J Neurol       Date:  2020-09-03       Impact factor: 4.849

Review 2.  Psychiatric disorders in multiple sclerosis.

Authors:  Maddalena Sparaco; Luigi Lavorgna; Simona Bonavita
Journal:  J Neurol       Date:  2019-06-13       Impact factor: 4.849

Review 3.  Wellness and the Role of Comorbidities in Multiple Sclerosis.

Authors:  Brandon P Moss; Mary R Rensel; Carrie M Hersh
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

4.  Predicting onset of secondary-progressive multiple sclerosis using genetic and non-genetic factors.

Authors:  Elina Misicka; Corriene Sept; Farren B S Briggs
Journal:  J Neurol       Date:  2020-04-24       Impact factor: 4.849

Review 5.  Mortality in patients with multiple sclerosis.

Authors:  Antonio Scalfari; Volker Knappertz; Gary Cutter; Douglas S Goodin; Raymond Ashton; George C Ebers
Journal:  Neurology       Date:  2013-07-09       Impact factor: 9.910

Review 6.  Caring for Women with Multiple Sclerosis Across the Lifespan.

Authors:  Kelsey Rankin; Riley Bove
Journal:  Curr Neurol Neurosci Rep       Date:  2018-05-23       Impact factor: 5.081

Review 7.  Management of pain in multiple sclerosis: a pharmacological approach.

Authors:  Claudio Solaro; Michele Messmer Uccelli
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

Review 8.  Hypothalamic Dysfunction and Multiple Sclerosis: Implications for Fatigue and Weight Dysregulation.

Authors:  Kevin G Burfeind; Vijayshree Yadav; Daniel L Marks
Journal:  Curr Neurol Neurosci Rep       Date:  2016-11       Impact factor: 5.081

Review 9.  Pain and multiple sclerosis: pathophysiology and treatment.

Authors:  Claudio Solaro; Erika Trabucco; Michele Messmer Uccelli
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

Review 10.  The outliers become a stampede as immunometabolism reaches a tipping point.

Authors:  Barbara S Nikolajczyk; Madhumita Jagannathan-Bogdan; Gerald V Denis
Journal:  Immunol Rev       Date:  2012-09       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.